---
layout: post
title: "Prospective Grant of an Exclusive Patent License: Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1, or TRAT1"
date: 2026-02-04 21:37:13 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-23691
original_published: 2025-12-23 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1, or TRAT1

**Published:** February 04, 2026 21:37 UTC
**Source:** Federal Register
**Original Published:** December 23, 2025 00:00 UTC
**Document Number:** 2025-23691

## Summary

The Eunice Kennedy Shriver National Institute of Child Health and Human Development, an institute of the National Institutes of Health, United States Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice to EnZeta Immunotherapies, Inc., a company located in Coral Gables, FL.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/12/23/2025-23691/prospective-grant-of-an-exclusive-patent-license-enhanced-tumor-reactivity-of-t-cells-lacking-sit1)
- API: https://www.federalregister.gov/api/v1/documents/2025-23691

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
